Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration?

Table 2

The ability of spectral-domain optical coherence tomography and time-domain optical coherence tomography to detect the vitreoretinal surface disorders.

Variables	TD-OCT	SD-OCT	P
ERM	7 patients	9 patients	0.7
PVD	2 patients	4 patients	0.4
VMT	1 patients	4 patients	0.19

ERM: epiretinal membrane; PVD: posterior vitreous detachment; VMT: vitreomacular traction, TD-OCT: time-domain optical coherence tomography; SD-OCT: spectral-domain optical coherence tomography; P: P value, chi-square test.